Physician profile
Blake Shusterman
NPI 1831301779
$66,417.49
in general payments reported to CMS, 2019-2025
32 companies · $1,327 in 2025
The $1,327 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $212 · 2021: $265 · 2022: $792 · 2023: $1,850 · 2024: $61K · 2025: $1,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $61K · Food and Beverage: $3,156 · Education: $61.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $61,377.00 |
| Food and Beverage | $3,156.00 |
| Education | $61.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $60,450.99 | 2019-2025 | Farxiga, Lokelma |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,258.69 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $500.69 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $445.85 | 2019-2025 | Krystexxa, Tavneos |
| Horizon Therapeutics Plc | $380.18 | 2019-2023 | Krystexxa |
| Travere Therapeutics, INC. | $353.23 | 2022-2025 | |
| Nxstage Medical, INC. | $322.32 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $322.23 | 2023-2025 | |
| Outset Medical INC | $317.55 | 2025 | |
| Vifor Pharma, INC. | $244.18 | 2019-2025 | Veltassa |
| Akebia Therapeutics INC | $239.91 | 2019-2025 | Vafseo, Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $212.47 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $212.37 | 2023-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $167.38 | 2022-2025 | Terlivaz |
| Bard Peripheral Vascular, INC. | $121.46 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $106.29 | 2022-2024 | Jesduvroq, Benlysta |
| Opko Pharmaceuticals, LLC | $104.73 | 2020-2023 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.68 | 2023-2025 | Jardiance |
| Baxter Healthcare | $76.40 | 2019 | |
| Ani Pharmaceuticals, INC. | $67.87 | 2022 | |
| Ardelyx, INC. | $61.71 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $50.58 | 2025 | Ozempic, Rivfloza |
| Mallinckrodt Enterprises LLC | $44.34 | 2019 | |
| Lilly USA, LLC | $37.51 | 2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $36.42 | 2021-2024 | Ultomiris |
| Genzyme Corporation | $35.76 | 2020-2023 | |
| Lundbeck LLC | $34.92 | 2019 | |
| Fresenius USA Marketing, INC. | $33.26 | 2020-2024 | Velphoro |
| Kyowa Kirin, INC. | $27.29 | 2025 | |
| Aurinia Pharma U.S., INC. | $20.95 | 2025 | Lupkynis |
| Biomerieux INC | $17.58 | 2019 | |
| Daiichi Sankyo INC. | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Shusterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.